Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs

The first biotech out of incubator and investor Jupiter Bioventures is working on a $75 million Series B to bring its first two drug candidates into clinical testing. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…

Source: Endpoints News